Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk

Detecting minimal disease that persists after treatment is a central diagnostic challenge, even with sensitive blood-based assays. Understanding where and how residual tumor cells survive could improve risk stratification and guide surveillance. Researchers now describe tissue-based molecular features in microscopic liver metastases that align with recurrence risk.

At the University of Texas MD Anderson Cancer Center, investigators identified a six-gene signature, called MicroMetSig, within microscopic colorectal cancer (CRC) liver metastases that may signal residual disease, recurrence risk, and chemotherapy resistance. Using comprehensive spatial analyses, the team examined how micrometastases evolve, evade immune surveillance, and persist after therapy. The signature is presented as a tissue-based complement to blood testing rather than a replacement.

The approach integrates high-resolution spatial profiling and multi-omics to compare gene activity across micrometastases, macrometastases, and adjacent noncancerous liver tissue. The analysis revealed a distinct micrometastatic tumor cell state with dormant, stem-like features. These features provide a biological context for why microscopic deposits can survive treatment yet remain undetectable by routine imaging.

Study sampling included 49 tumors from 19 patients with primary CRC and matched liver and lung metastases. Circulating tumor DNA (ctDNA) assays can signal minimal residual disease (MRD), but they do not localize residual cells or explain survival mechanisms. By directly profiling tissue, the study suggests that liver micrometastases offer a window into MRD biology and relapse pathways.

Higher expression of the signature, described as MicroMetSig-high, was associated with shorter disease-free and MRD-free survival, as well as increased recurrence risk and chemotherapy resistance across multiple patient datasets. Spatial maps also showed micrometastases surrounded by immune cells with signs of exhaustion, along with immunosuppressive signaling that included PD-1/PD-L1 pathways. The authors noted that larger validation cohorts and functional studies are needed to clarify how these dormant cells suppress immunity and persist after treatment.

The findings were published on July 9, 2026, in Cancer Cell. The authors emphasize that, if validated, the six-gene signature could help connect blood-based MRD testing with the tissue context that drives relapse and inform closer monitoring or additional post-surgical interventions.

"These findings provide critical insights into how colorectal cancer cells can hide after treatment and later return, suggesting that tissue-based markers could complement blood-based tests to help identify patients at higher risk of recurrence, While this gene signature needs validation in larger cohorts to establish clinical efficacy, we are encouraged by the translational relevance of these results," said Dipen Maru, M.D., professor of Anatomical Pathology, University of Texas MD Anderson Cancer Center.

"Micrometastases are not simply smaller versions of macrometastases, but rather they appear to represent a distinct biological state, Using spatial multi-omics and computational analysis, we were able to compare microscopic and larger metastases directly in tissue to help identify programs linked with tumor persistence and disease recurrence. These approaches may help bridge blood-based MRD testing with the tissue biology that drives relapse," stated Linghua Wang, M.D., Ph.D., professor of Genomic Medicine, University of Texas MD Anderson Cancer Center.

Related Links
UT MD Anderson Cancer Center